Claris Ventures Holds First Close of Maiden Fund, at $30M
Summary
Founded by Pietro Puglisi and Ciro Spedaliere, Claris will mainly invest in Italian companies with therapeutic compounds possibly addressing highly unmet clinical needs. The firm will lead €5-15m financing rounds, aiming at providing adequate resources to get to a clinical proof-of-concept, typically completing a Phase 1/2a study. Commenting on the announcement, Pietro Puglisi said: “Contributing to the development of new therapies and, at the same time, creating value and economic impact is a challenge we are honored to accept. “The passage from preclinical to clinical development is crucial for the future of new biopharma ventures: our exclusive focus allows us to curate every little detail, maximize the probability of success,” he added. Understanding the fundamental logic of different ecosystems is key to provide strategic insights to our portfolio companies,” Ciro Spedaliere said.